Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(14):1183-1184; doi:10.1093/jnci/92.14.1183
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Magnusson, C.
Right arrow Articles by Adami, H.-O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Magnusson, C.
Right arrow Articles by Adami, H.-O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 14, 1183-1184, July 19, 2000
© 2000 Oxford University Press

CORRESPONDENCE

More About: Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin

Cecilia Magnusson, Ingemar Persson, Hans-Olov Adami

Affiliation of authors: C. Magnusson, I. Persson, Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden; H.-O. Adami, Department of Medical Epidemiology, Karolinska Institutet, and Department of Epidemiology and Harvard Center for Cancer Prevention, Harvard University, Boston, MA.

Correspondence to: Cecilia Magnusson, M.D., Ph.D., Department of Medical Epidemiology, Karolinska Institutet, P.O. Box 281, 171 77 Stockholm, Sweden (e-mail: Cecilia.Magnusson@mep.ki.se).

The influence of combined estrogen–progestin replacement therapy on breast cancer risk is important in the risk–benefit equation associated with hormone replacement therapy. Thus, the lack of data on this relationship is of considerable concern to the millions of treated women. Therefore, it was with great interest we read the report in the Journal by Ross et al. (1). Last year, . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
N. Biglia, L. Mariani, L. Sgro, P. Mininanni, G. Moggio, and P. Sismondi
Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment
Endocr. Relat. Cancer, September 1, 2007; 14(3): 549 - 567.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. D. Aupperlee, K. T. Smith, A. Kariagina, and S. Z. Haslam
Progesterone Receptor Isoforms A and B: Temporal and Spatial Differences in Expression during Murine Mammary Gland Development
Endocrinology, August 1, 2005; 146(8): 3577 - 3588.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
J M Dixon
Hormone replacement therapy and the breast
BMJ, December 15, 2001; 323(7326): 1381 - 1382.
[Full Text] [PDF]